Selected research
Industry Research
Nintedanib Generics Industry Research Report 2026
Market perspective
The global Nintedanib Generics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Nintedanib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Nintedanib Generics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Nintedanib Generics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Nintedanib Generics include CSPC Pharmaceutical Group, PuraCap, Qilu Pharmaceutical, Kelun Pharmaceutical, Jiangsu Wangao Pharmaceutical, Glenmark, Eskayef Pharmaceuticals, Cipla and Beacon Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Nintedanib Generics market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nintedanib Generics Market by Company
CSPC Pharmaceutical Group
PuraCap
Qilu Pharmaceutical
Kelun Pharmaceutical
Jiangsu Wangao Pharmaceutical
Glenmark
Eskayef Pharmaceuticals
Cipla
Beacon Pharma
Nintedanib Generics Segment by Type
100mg per Unit
150mg per Unit
Nintedanib Generics Segment by Application
Non-small Cell Lung Cancer
Idiopathic Pulmonary Fibrosis
Other
Nintedanib Generics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nintedanib Generics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nintedanib Generics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nintedanib Generics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Nintedanib Generics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Nintedanib Generics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Nintedanib Generics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 100mg per Unit
- 150mg per Unit
Applications
- Non-small Cell Lung Cancer
- Idiopathic Pulmonary Fibrosis
- Other
Companies covered
- CSPC Pharmaceutical Group
- PuraCap
- Qilu Pharmaceutical
- Kelun Pharmaceutical
- Jiangsu Wangao Pharmaceutical
- Glenmark
- Eskayef Pharmaceuticals
- Cipla
- Beacon Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Nintedanib Generics Market Size (2021-2032)
- 2.2.2 Global Nintedanib Generics Sales (2021-2032)
- 2.2.3 Global Nintedanib Generics Market Average Price (2021-2032)
- 2.3 Nintedanib Generics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 100mg per Unit
- 2.3.3 150mg per Unit
- 2.4 Nintedanib Generics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Non-small Cell Lung Cancer
- 2.4.3 Idiopathic Pulmonary Fibrosis
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Nintedanib Generics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Nintedanib Generics Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Nintedanib Generics Revenue of Manufacturers (2021-2026)
- 3.4 Global Nintedanib Generics Average Price by Manufacturers (2021-2026)
- 3.5 Global Nintedanib Generics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Nintedanib Generics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Nintedanib Generics, Product Type & Application
- 3.8 Global Manufacturers of Nintedanib Generics, Established Date
- 3.9 Global Nintedanib Generics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CSPC Pharmaceutical Group
- 4.1.1 CSPC Pharmaceutical Group Company Information
- 4.1.2 CSPC Pharmaceutical Group Business Overview
- 4.1.3 CSPC Pharmaceutical Group Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CSPC Pharmaceutical Group Nintedanib Generics Product Portfolio
- 4.1.5 CSPC Pharmaceutical Group Recent Developments
- 4.2 PuraCap
- 4.2.1 PuraCap Company Information
- 4.2.2 PuraCap Business Overview
- 4.2.3 PuraCap Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 PuraCap Nintedanib Generics Product Portfolio
- 4.2.5 PuraCap Recent Developments
- 4.3 Qilu Pharmaceutical
- 4.3.1 Qilu Pharmaceutical Company Information
- 4.3.2 Qilu Pharmaceutical Business Overview
- 4.3.3 Qilu Pharmaceutical Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Qilu Pharmaceutical Nintedanib Generics Product Portfolio
- 4.3.5 Qilu Pharmaceutical Recent Developments
- 4.4 Kelun Pharmaceutical
- 4.4.1 Kelun Pharmaceutical Company Information
- 4.4.2 Kelun Pharmaceutical Business Overview
- 4.4.3 Kelun Pharmaceutical Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Kelun Pharmaceutical Nintedanib Generics Product Portfolio
- 4.4.5 Kelun Pharmaceutical Recent Developments
- 4.5 Jiangsu Wangao Pharmaceutical
- 4.5.1 Jiangsu Wangao Pharmaceutical Company Information
- 4.5.2 Jiangsu Wangao Pharmaceutical Business Overview
- 4.5.3 Jiangsu Wangao Pharmaceutical Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Jiangsu Wangao Pharmaceutical Nintedanib Generics Product Portfolio
- 4.5.5 Jiangsu Wangao Pharmaceutical Recent Developments
- 4.6 Glenmark
- 4.6.1 Glenmark Company Information
- 4.6.2 Glenmark Business Overview
- 4.6.3 Glenmark Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Glenmark Nintedanib Generics Product Portfolio
- 4.6.5 Glenmark Recent Developments
- 4.7 Eskayef Pharmaceuticals
- 4.7.1 Eskayef Pharmaceuticals Company Information
- 4.7.2 Eskayef Pharmaceuticals Business Overview
- 4.7.3 Eskayef Pharmaceuticals Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Eskayef Pharmaceuticals Nintedanib Generics Product Portfolio
- 4.7.5 Eskayef Pharmaceuticals Recent Developments
- 4.8 Cipla
- 4.8.1 Cipla Company Information
- 4.8.2 Cipla Business Overview
- 4.8.3 Cipla Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Cipla Nintedanib Generics Product Portfolio
- 4.8.5 Cipla Recent Developments
- 4.9 Beacon Pharma
- 4.9.1 Beacon Pharma Company Information
- 4.9.2 Beacon Pharma Business Overview
- 4.9.3 Beacon Pharma Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Beacon Pharma Nintedanib Generics Product Portfolio
- 4.9.5 Beacon Pharma Recent Developments
5 Global Nintedanib Generics Market Scenario by Region
- 5.1 Global Nintedanib Generics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Nintedanib Generics Sales by Region: 2021-2032
- 5.2.1 Global Nintedanib Generics Sales by Region: 2021-2026
- 5.2.2 Global Nintedanib Generics Sales by Region: 2027-2032
- 5.3 Global Nintedanib Generics Revenue by Region: 2021-2032
- 5.3.1 Global Nintedanib Generics Revenue by Region: 2021-2026
- 5.3.2 Global Nintedanib Generics Revenue by Region: 2027-2032
- 5.4 North America Nintedanib Generics Market Facts & Figures by Country
- 5.4.1 North America Nintedanib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Nintedanib Generics Sales by Country (2021-2032)
- 5.4.3 North America Nintedanib Generics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Nintedanib Generics Market Facts & Figures by Country
- 5.5.1 Europe Nintedanib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Nintedanib Generics Sales by Country (2021-2032)
- 5.5.3 Europe Nintedanib Generics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Nintedanib Generics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Nintedanib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Nintedanib Generics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Nintedanib Generics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Nintedanib Generics Market Facts & Figures by Country
- 5.7.1 South America Nintedanib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Nintedanib Generics Sales by Country (2021-2032)
- 5.7.3 South America Nintedanib Generics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Nintedanib Generics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Nintedanib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Nintedanib Generics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Nintedanib Generics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Nintedanib Generics Sales by Type (2021-2032)
- 6.1.1 Global Nintedanib Generics Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Nintedanib Generics Sales Market Share by Type (2021-2032)
- 6.2 Global Nintedanib Generics Revenue by Type (2021-2032)
- 6.2.1 Global Nintedanib Generics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Nintedanib Generics Revenue Market Share by Type (2021-2032)
- 6.3 Global Nintedanib Generics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Nintedanib Generics Sales by Application (2021-2032)
- 7.1.1 Global Nintedanib Generics Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Nintedanib Generics Sales Market Share by Application (2021-2032)
- 7.2 Global Nintedanib Generics Revenue by Application (2021-2032)
- 7.2.1 Global Nintedanib Generics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Nintedanib Generics Revenue Market Share by Application (2021-2032)
- 7.3 Global Nintedanib Generics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Nintedanib Generics Value Chain Analysis
- 8.1.1 Nintedanib Generics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Nintedanib Generics Production Mode & Process
- 8.2 Nintedanib Generics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Nintedanib Generics Distributors
- 8.2.3 Nintedanib Generics Customers
9 Global Nintedanib Generics Analyzing Market Dynamics
- 9.1 Nintedanib Generics Industry Trends
- 9.2 Nintedanib Generics Industry Drivers
- 9.3 Nintedanib Generics Industry Opportunities and Challenges
- 9.4 Nintedanib Generics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst